Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVID SCIENCE-Delta variant gains ground in U.S., men do worse with COVID-19

06/30/2021 | 01:46pm EDT

June 30 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Highly contagious Delta variant gaining ground in U.S.

The highly transmissible Delta variant of SARS-CoV-2, first identified in India, has become the most prevalent variant among new COVID-19 cases in the United States, according to California-based genomics company Helix. The company's computer models indicate that Delta now accounts for around 40% of new U.S. cases, Dr. William Lee, vice president of science at Helix, said in a statement provided to Reuters. The models, based on 27,717 virus samples from 687 counties across the United States, also indicated that the worrisome Gamma variant, first identified in Brazil, accounts for about 15% of new cases. Helix researchers have noted occasional cases of an "offspring" variant of Delta called Delta-plus, but they "aren't seeing any evidence suggesting that these are driving the growth of Delta around the country yet," Lee said. Earlier in June, the researchers reported on the medical website medRxiv ahead of peer review that the percentage of new COVID-19 cases due to the variant first identified in Britain, known as Alpha, had dropped from 70% in mid-April 2021 to 42% six weeks later (https://bit.ly/3x45vBW). Now, Lee said, Alpha "is down to around 20%." Lee said his team has submitted an update to the previous medRxiv preprint and is waiting for approval.

Regardless of health status, men do worse with COVID-19

Men appear more likely than women to experience severe outcomes from COVID-19 regardless of whether the men have underlying health conditions, according to a new study. Researchers in New York City who tracked roughly 5,000 patients of both sexes who were diagnosed in early 2020 found that men were sicker when first diagnosed and had a higher need for intensive care treatment and higher rates of death than women. This was true even though the men on average were younger and less likely than women to have risk factors such as obesity and high blood pressure that previously have been linked with poor COVID-19 outcomes. Among women, the likelihood of severe COVID-19 outcomes did seem to be related to their health status, the researchers said in a report published on Wednesday in the journal Communications Medicine. A second analysis of another group of roughly 1,600 patients in New York City diagnosed later in the year showed similar patterns. The authors noted that because their information on patients' pre-existing medical problems may have been incomplete, larger studies are needed to confirm their findings and to explain the causes. (https://go.nature.com/3jpdWUG)

Moderna vaccine antibodies neutralize variants in lab study

The mRNA vaccine from Moderna Inc can defend against emerging variants with only modestly reduced effectiveness, laboratory experiments indicated. Moderna researchers studied blood serum obtained from eight volunteers who had received the second dose of the vaccine a week earlier. They found the vaccine had produced antibodies capable of neutralizing all variants, including additional versions of the Beta variant first identified in South Africa and three lineages of variants first identified in India, including the Kappa and Delta variants. The analysis did show some reduction of neutralization, by 2.1 fold against Delta, 3.3-3.4 fold against Kappa and 3.2 fold against Gamma, which was first identified in Brazil. "These new data are encouraging and reinforce our belief that the Moderna COVID-19 vaccine should remain protective against newly detected variants," Moderna Chief Executive Stéphane Bancel said. The Moderna data was posted on Monday on the bioRxiv medical website ahead of peer review. Earlier in June, researchers reported in the journal Nature that the mRNA vaccine from Pfizer and BioNTech elicited antibodies that could neutralize all tested variants, including Delta, although at reduced strength.

Open https://tmsnrt.rs/3c7R3Bl in an external browser for a Reuters graphic on vaccines in development.

(Reporting by Nancy Lapid and Mrinalika Roy; Editing by Will Dunham)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BASICNET S.P.A. -0.53% 4.735 Delayed Quote.13.82%
BIONTECH SE -5.53% 333.48 Delayed Quote.309.08%
DOW JONES AFRICA TITANS 50 INDEX -0.12% 511.21 Delayed Quote.-2.97%
DOW JONES SOUTH AFRICA(ZAR) 0.00% 1869.66 Delayed Quote.6.01%
EURO / BRAZILIAN REAL (EUR/BRL) 0.47% 6.2556 Delayed Quote.-1.87%
MODERNA, INC. -5.38% 430.14 Delayed Quote.311.74%
PFIZER, INC. -0.57% 43.94 Delayed Quote.20.05%
S&P AFRICA 40 INDEX -0.44% 165.74 Delayed Quote.-3.54%
All news about MODERNA, INC.
09/24INSIDER SELL : Moderna
MT
09/24MODERNA : COVID SCIENCE-Vaccinated pregnant women pass protective antibodies to babies
RE
09/24MODERNA : U.S. administers 388.6 mln doses of COVID-19 vaccines - CDC
RE
09/24MODERNA : U.S. CDC Says 182,958,696 Individuals Have Been Fully Vaccinated Against COVID-1..
RE
09/24MODERNA : CDC director says boosters needed to protect workers
RE
09/24Equities Fluctuate Midday as Real Estate, Tech Among Worst Performers
MT
09/24EXPLAINER : Who's eligible for Pfizer booster shots in US?
AQ
09/24WALGREENS BOOTS ALLIANCE : Who can get a COVID-19 vaccine booster in the United States?
RE
09/24MIDDAY REPORT : US Stocks Fluctuate as Real Estate, Tech Among Worst Performers; Digital C..
MT
09/24US AF : Myths and facts about the vax - debunking common COVID-19 vaccine myths
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 333 M - -
Net income 2021 12 514 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 14,5x
Yield 2021 -
Capitalization 174 B 174 B -
EV / Sales 2021 7,90x
EV / Sales 2022 7,19x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 430,14 $
Average target price 307,77 $
Spread / Average Target -28,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353
PHARMARON BEIJING CO., LTD.79.90%25 236